Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 2:13 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 649 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Vaccine Response Clear all
Recruiting Not applicable Interventional Accepts healthy volunteers

Optimizing Lymphatic Pumping for Influenza Vaccine Responses in Vulnerable Populations

NCT07786467
View directory record Official record
Conditions
No Disease or Condition is Being Directly Studied, The Focus of the Study in Healthy Volunteers
Interventions
Osteopathic manipulation, Sham
Other
Lead sponsor
Lake Erie College of Osteopathic Medicine
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Erie, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 22, 2026, 2:13 AM EDT
Completed Phase 2 Interventional

Dryvax Dilution-Prev Vacc Adults

NCT00032708
View directory record Official record
Conditions
Smallpox
Interventions
Dryvax
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
90 participants
Timeline
2004
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 27, 2010 · Synced Oct 22, 2026, 2:13 AM EDT
Completed Phase 2 Interventional Results available

QUILT-3.006 for Recurrent Medullary Thyroid Cancer

NCT01856920
View directory record Official record
Conditions
Medullary Thyroid Cancer (MTC)
Interventions
GI-6207 [Recombinant Saccharomyces cerevisiae-CEA (610D)]
Biological
Lead sponsor
NantCell, Inc.
Industry
Eligibility
18 Years to 100 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 9, 2024 · Synced Oct 22, 2026, 2:13 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Immune Response After a Booster Dose of a Quadrivalent Meningococcal (MenACYW) Conjugate Vaccine When Administered Alone or Concomitantly With a Licensed Meningococcal Serogroup B Vaccine, in Participants Who Received Primary Quadrivalent Meningococcal Conjugate Vaccine (MCV4)

NCT04084769
View directory record Official record
Conditions
Meningococcal Immunisation (Healthy Volunteers)
Interventions
Meningococcal polysaccharide (serogroups A, C, Y, and W) tetanus toxoid Conjugate vaccine MenACYW Conjugate vaccine, Meningococcal Group B vaccine (Trumenba®), Meningococcal group B vaccine (Bexsero®)
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
13 Years to 26 Years
Enrollment
570 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
29
States / cities
Birmingham, Alabama • San Diego, California • Bardstown, Kentucky + 20 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2025 · Synced Oct 22, 2026, 2:13 AM EDT
Withdrawn Phase 3 Interventional Accepts healthy volunteers

A Study of Safety, Reactogenicity and Immune Response of the Repeat Vaccination Against RSV When Given to Female Participants of 18-49 Years of Age During Their Subsequent Uncomplicated Pregnancy

NCT05229068
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
RSV MAT
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 49 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
2
States / cities
Missoula, Montana • Norfolk, Nebraska
Source: ClinicalTrials.gov public record
Updated Apr 7, 2022 · Synced Oct 22, 2026, 2:13 AM EDT
Completed Phase 2 Interventional Results available

Prospective Trial of Vaccine Responses in Childhood Cancer Survivors

NCT00505063
View directory record Official record
Conditions
Childhood Cancer, Multiple Diseases
Interventions
Immunization Schedule patients <7 years., Immunization Schedule patients > or = to 7 years and <11 years of age, Immunization Schedule patients > or = to 11 years of age
Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
2 Years to 18 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 22, 2026, 2:13 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

The Long-term Antibody Persistence of GSK Biologicals' Meningococcal Vaccine GSK134612 in Healthy Adolescents/Adults

NCT00715910
View directory record Official record
Conditions
Infections, Meningococcal
Interventions
Nimenrix, Blood sampling
Biological · Procedure
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
15 Years to 30 Years
Enrollment
818 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2013
U.S. locations
10
States / cities
Daly City, California • Fairfield, California • Redwood City, California + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 27, 2014 · Synced Oct 22, 2026, 2:13 AM EDT
Completed Phase 1 Interventional

Safety and Immune Response Assessment Study of Killed-whole HIV-1 Vaccine (SAV001-H) in Chronic HIV-1 Infected Patients

NCT01546818
View directory record Official record
Conditions
HIV Infections
Interventions
SAV001-H
Biological
Lead sponsor
Sumagen
Industry
Eligibility
18 Years to 50 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 9, 2013 · Synced Oct 22, 2026, 2:13 AM EDT
Completed Phase 2 Interventional Results available

A Study to Test if the Vaccine is Working Well in Chronic Obstructive Pulmonary Disease (COPD) Patients Aged 40 to 80 Years Old to Reduce Episodes of Worsening Symptoms and to Gather Further Information on Safety and Immune Response.

NCT03281876
View directory record Official record
Conditions
Respiratory Disorders
Interventions
NTHi Mcat investigational vaccine (GSK3277511A), Placebo
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years to 80 Years
Enrollment
606 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
25
States / cities
Mesa, Arizona • Phoenix, Arizona • Palm Springs, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2021 · Synced Oct 22, 2026, 2:13 AM EDT
Completed Phase 2 Interventional

Evaluation and Treatment of Eye Complications of Vaccinia Vaccination

NCT00081835
View directory record Official record
Conditions
Vaccinia
Interventions
NP-016 Vaccine Immune Globulin (IV-VIG)
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
1 Year and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 22, 2026, 2:13 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of and Immune Response to Two Different Dengue Virus Vaccines in Individuals Previously Immunized Against Dengue Virus

NCT00458120
View directory record Official record
Conditions
Dengue Hemorrhagic Fever
Interventions
rDEN1delta30, rDEN2/4delta30(ME), Placebo to rDEN1delta30 or rDEN2/4delta30(ME)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 14, 2010 · Synced Oct 22, 2026, 2:13 AM EDT
Completed Phase 4 Interventional

VSMART (Video-Conference Stress Management and Relaxation Training for Older Women With Breast Cancer)

NCT03955991
View directory record Official record
Conditions
Stress
Interventions
R-CBSM, Influenza vaccine
Behavioral · Biological
Lead sponsor
University of Miami
Other
Eligibility
50 Years and older · Female only
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
1
States / cities
Coral Gables, Florida
Source: ClinicalTrials.gov public record
Updated Jun 26, 2025 · Synced Oct 22, 2026, 2:13 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study to Assess Gonorrhoeae Immune Responses Induced by a N. Meningitidis Vaccine

NCT04094883
View directory record Official record
Conditions
Neisseria Gonorrhoeae Infection
Interventions
Meningococcal Group B Vaccine
Biological
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 25 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 15, 2021 · Synced Oct 22, 2026, 2:13 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study Evaluating the Impact of the 13-valent Pneumococcal Conjugate Vaccine (13vPnC) in Alaskan Native Children.

NCT00743652
View directory record Official record
Conditions
Pneumococcal Disease, 13-valent Pneumococcal Vaccine
Interventions
13-valent Pneumococcal Conjugate Vaccine
Biological
Lead sponsor
Pfizer
Industry
Eligibility
42 Days to 5 Years
Enrollment
373 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
21
States / cities
Akiak, Alaska • Bethel, Alaska • Chefornak, Alaska + 18 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2012 · Synced Oct 22, 2026, 2:13 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Salmonella Conjugates CVD 1000: Study of Responses to Vaccination With Trivalent Invasive Salmonella Disease Vaccine

NCT03981952
View directory record Official record
Conditions
Risk Reduction
Interventions
Trivalent Invasive Salmonella Disease Vaccine (6.25 µg), Trivalent Invasive Salmonella Disease Vaccine (12 µg), Trivalent Invasive Salmonella Disease Vaccine (25 µg), Trivalent Invasive Salmonella Disease Vaccine (highest, well-tolerated dose among Cohorts A-C), Placebo
Biological · Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 45 Years
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 11, 2025 · Synced Oct 22, 2026, 2:13 AM EDT
Completed Phase 1 Interventional Results available

Safety and Immunogenicity of an Epstein-Barr Virus (EBV) gp350-Ferritin Nanoparticle Vaccine in Healthy Adults

NCT04645147
View directory record Official record
Conditions
EBV, Epstein-Barr Virus Infection, Infectious Mononucleosis
Interventions
EBV gp350-Ferritin Vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 29 Years
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 22, 2026, 2:13 AM EDT
Completed Phase 1 Interventional

Vaccine Therapy in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma

NCT00104845
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
human gp100 plasmid DNA vaccine, mouse gp100 plasmid DNA vaccine
Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Not listed
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 12, 2013 · Synced Oct 22, 2026, 2:13 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Study to Evaluate the Immune Response and Safety of an Influenza Vaccine in Adults 18 Years of Age and Above

NCT07204964
View directory record Official record
Conditions
Influenza, Human
Interventions
Flu mRNA (Formulation B1), Flu mRNA (Formulation B3), Flu mRNA(Formulation A), Comparator 1, Comparator 2, Comparator 3
Biological · Combination Product
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
971 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
15
States / cities
Guntersville, Alabama • Canoga Park, California • Walnut Creek, California + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 22, 2026, 2:13 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effect of Antimalarial Drugs to Rabies Vaccine for Post-exposure Prophylaxis.

NCT02564471
View directory record Official record
Conditions
Rabies
Interventions
Chloroquine, Atovaquone and Proguanil, Doxycycline, Rabies Vaccine
Drug · Biological
Lead sponsor
State University of New York - Upstate Medical University
Other
Eligibility
18 Years to 60 Years
Enrollment
103 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated May 13, 2021 · Synced Oct 22, 2026, 2:13 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Systems Biology of Zoster Vaccine (ZOSTAVAX®) in Young and Elderly

NCT01331161
View directory record Official record
Conditions
Shingles
Interventions
ZOSTAVAX
Biological
Lead sponsor
Emory University
Other
Eligibility
25 Years to 79 Years
Enrollment
77 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
2
States / cities
Aurora, Colorado • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 17, 2016 · Synced Oct 22, 2026, 2:13 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of and Immune Response to a DNA HIV Vaccine (pGA2/JS7) Boosted With a Modified Vaccinia HIV Vaccine (MVA/HIV62) in Healthy Adults

NCT00301184
View directory record Official record
Conditions
HIV Infections
Interventions
pGA2/JS7 DNA, Modified vaccinia Ankara/HIV62
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
6
States / cities
Birmingham, Alabama • Baltimore, Maryland • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2022 · Synced Oct 22, 2026, 2:13 AM EDT
Completed Phase 2 Interventional Results available

Enzalutamide With or Without Vaccine Therapy for Advanced Prostate Cancer

NCT01867333
View directory record Official record
Conditions
Prostate Cancer
Interventions
PROSTVAC (rilimogene galvacirepvec/rilimogene glafolivec) -F/TRICOM, PROSTVAC (rilimogene galvacirepvec/rilimogene glafolivec) -V/TRICOM, Enzalutamide
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 26, 2023 · Synced Oct 22, 2026, 2:13 AM EDT
Completed No phase listed Observational

Response to SARS-CoV-2 Vaccine in Stem Cell Transplant and Cellular Therapy Patients

NCT04723706
View directory record Official record
Conditions
Hematologic Disorders and Bone Marrow Failure, Hematopoietic Stem Cell Transplantation (HSCT) or Cellular Therapy (CART)
Interventions
COVID-19 serology IgG
Diagnostic Test
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years to 80 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 23, 2024 · Synced Oct 22, 2026, 2:13 AM EDT
Completed Phase 1 Interventional

Experimental PfSPZ Vaccine in Adults Without Malaria

NCT01441167
View directory record Official record
Conditions
Malaria, Prevention and Control, Acquired Immunity
Interventions
PfSPZ
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 5, 2018 · Synced Oct 22, 2026, 2:13 AM EDT